These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. The diagnosis and management of Barrett's esophagus. DeMeester SR; DeMeester TR Adv Surg; 1999; 33():29-68. PubMed ID: 10572561 [TBL] [Abstract][Full Text] [Related]
7. Circulating tumor cells and circulating tumor DNA: What surgical oncologists need to know? Cabel L; Proudhon C; Mariani P; Tzanis D; Beinse G; Bieche I; Pierga JY; Bidard FC Eur J Surg Oncol; 2017 May; 43(5):949-962. PubMed ID: 28185687 [TBL] [Abstract][Full Text] [Related]
8. Evolving screening and surveillance techniques for Barrett's esophagus. Steele D; Baig KKK; Peter S World J Gastroenterol; 2019 May; 25(17):2045-2057. PubMed ID: 31114132 [TBL] [Abstract][Full Text] [Related]
9. Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling. Garside R; Pitt M; Somerville M; Stein K; Price A; Gilbert N Health Technol Assess; 2006 Mar; 10(8):1-142, iii-iv. PubMed ID: 16545207 [TBL] [Abstract][Full Text] [Related]
10. Surveillance of premalignant gastric lesions: a multicentre prospective cohort study from low incidence regions. den Hollander WJ; Holster IL; den Hoed CM; Capelle LG; Tang TJ; Anten MP; Prytz-Berset I; Witteman EM; Ter Borg F; Hartog GD; Bruno MJ; Peppelenbosch MP; Lesterhuis W; Doukas M; Kuipers EJ; Spaander MCW Gut; 2019 Apr; 68(4):585-593. PubMed ID: 29875257 [TBL] [Abstract][Full Text] [Related]
11. Barrett's oesophagus: a review of costs of the illness. Arguedas MR; Eloubeidi MA Pharmacoeconomics; 2001; 19(10):1003-11. PubMed ID: 11735670 [TBL] [Abstract][Full Text] [Related]
12. Risk factors and populations at risk: selection of patients for screening for Barrett's oesophagus. Rubenstein JH; Thrift AP Best Pract Res Clin Gastroenterol; 2015 Feb; 29(1):41-50. PubMed ID: 25743455 [TBL] [Abstract][Full Text] [Related]
13. Barrett's oesophagus: can meaningful screening and surveillance guidelines be formulated based on new data and rejigging the old paradigm? Rajendra S Best Pract Res Clin Gastroenterol; 2015 Feb; 29(1):65-75. PubMed ID: 25743457 [TBL] [Abstract][Full Text] [Related]
14. Surveillance in Barrett's esophagus: a failed premise. Inadomi JM Keio J Med; 2009 Mar; 58(1):12-8. PubMed ID: 19398879 [TBL] [Abstract][Full Text] [Related]
15. Grail to pour $1 billion into blood test to detect early cancer. Sheridan C Nat Biotechnol; 2017 Feb; 35(2):101-102. PubMed ID: 28178244 [No Abstract] [Full Text] [Related]
16. Cost considerations in implementing a screening and surveillance strategy for Barrett's oesophagus. Inadomi JM Best Pract Res Clin Gastroenterol; 2015 Feb; 29(1):51-63. PubMed ID: 25743456 [TBL] [Abstract][Full Text] [Related]
17. The rationale for screening and surveillance of Barrett's metaplasia. Wani S; Sharma P Best Pract Res Clin Gastroenterol; 2006; 20(5):829-42. PubMed ID: 16997164 [TBL] [Abstract][Full Text] [Related]
18. Autoantibodies: Opportunities for Early Cancer Detection. Macdonald IK; Parsy-Kowalska CB; Chapman CJ Trends Cancer; 2017 Mar; 3(3):198-213. PubMed ID: 28718432 [TBL] [Abstract][Full Text] [Related]
19. The Rationale and Efficacy of Primary and Secondary Prevention in Adenocarcinomas of the Upper Gastrointestinal Tract. Bornschein J; Bird-Lieberman EL; Malfertheiner P Dig Dis; 2019; 37(5):381-393. PubMed ID: 30970344 [TBL] [Abstract][Full Text] [Related]
20. Review article: emerging techniques for screening and surveillance in Barrett's oesophagus. Sharma P Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 5():63-70; discussion 95-6. PubMed ID: 15456467 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]